EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 31 / Numéro 2 (Février 2015) Med Sci (Paris), 31 2 (2015) 197-202 Références
Chémobiologie
Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 2, Février 2015
Chémobiologie
Page(s) 197 - 202
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20153102017
Publié en ligne 4 mars 2015
  1. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996 ; 274 : 1531–1534. [CrossRef] [PubMed] [Google Scholar]
  2. Kuo LC. Fragment-based drug design : tools, practical approches and examples. Methods in enzymology, vol. 493. London : Academic Press, 2011 : 592 p. [Google Scholar]
  3. Congreve M, Carr R, Murray C, Jhoti H. A rule of three for fragment-based lead discovery? Drug Discov Today 2003 ; 8 : 876–877. [CrossRef] [Google Scholar]
  4. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004 ; 9 : 430–431. [CrossRef] [PubMed] [Google Scholar]
  5. Wells JA, Mcclendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007 ; 450 : 1001–1009. [CrossRef] [PubMed] [Google Scholar]
  6. Erlanson DA. Introduction to fragment-based drug discovery. Top Curr Chem 2012 ; 317 : 1–32. [CrossRef] [PubMed] [Google Scholar]
  7. Zartler ED, Shapiro MJ. Fragment-based drug discovery: a practical approach. New York : John Wiley and Sons Ltd, 2008 : 286 p. [Google Scholar]
  8. Dalvit C. NMR methods in fragment screening: theory and a comparison with other biophysical techniques. Drug Discov Today 2009 ; 14 : 1051–1057. [CrossRef] [PubMed] [Google Scholar]
  9. Cala O, Guilliere F, Krimm I. NMR-based analysis of protein-ligand interactions. Anal Bioanal Chem 2014 ; 406 : 943–956. [CrossRef] [PubMed] [Google Scholar]
  10. Davies DR. Screening ligands by X-ray crystallography. Methods Mol Biol 2014 ; 1140 : 315–323. [CrossRef] [PubMed] [Google Scholar]
  11. Navratilova I, Hopkins AL. Emerging role of surface plasmon resonance in fragment-based drug discovery. Future Med Chem 2011 ; 3 : 1809–1820. [CrossRef] [PubMed] [Google Scholar]
  12. Maple HJ, Garlish RA, Rigau-Roca L, et al. Automated protein-ligand interaction screening by mass spectrometry. J Med Chem 2012 ; 55 : 837–851. [CrossRef] [PubMed] [Google Scholar]
  13. Meiby E, Simmonite H, Le Strat L, et al. Fragment screening by weak affinity chromatography: comparison with established techniques for screening against HSP90. Anal Chem 2013 ; 85 : 6756–6766. [CrossRef] [PubMed] [Google Scholar]
  14. Silvestre HL, Blundell TL, Abell C, et al. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proc Natl Acad Sci USA 2013 ; 110 : 12984–12989. [CrossRef] [Google Scholar]
  15. Hajduk PJ, Huth JR, Tse C. Predicting protein druggability. Drug Discov Today 2005 ; 10 : 1675–1682. [CrossRef] [PubMed] [Google Scholar]
  16. Baker M.. Fragment-based lead discovery grows up. Nat Rev Drug Discov 2013 ; 12 : 5–7. [CrossRef] [PubMed] [Google Scholar]
  17. Scott DE, Coyne AG, Hudson SA, Abell C. Fragment-based approaches in drug discovery and chemical biology. Biochemistry 2012 ; 51 : 4990–5003. [CrossRef] [PubMed] [Google Scholar]
  18. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008 ; 105 : 3041–3046. [CrossRef] [Google Scholar]
  19. Barelier S, Krimm I. Ligand specificity, privileged substructures and protein druggability from fragment-based screening. Curr Opin Chem Biol 2011 ; 15 : 469–474. [CrossRef] [PubMed] [Google Scholar]
  20. Barelier S, Pons J, Marcillat O, et al. Fragment-based deconstruction of Bcl-xL inhibitors. J Med Chem 2010 ; 53 : 2577–2588. [CrossRef] [PubMed] [Google Scholar]
  21. Barelier S, Pons J, Gehring K, et al. Ligand specificity in fragment-based drug design. J Med Chem 2010 ; 53 : 5256–5266. [CrossRef] [PubMed] [Google Scholar]
  22. Barelier S, Linard D, Pons J, et al. Discovery of fragment molecules that bind the human peroxiredoxin 5 active site. PLoS One 2010 ; 5 : e9744. [CrossRef] [PubMed] [Google Scholar]
  23. Krimm I, Lancelin JM, Praly JP. Binding evaluation of fragment-based scaffolds for probing allosteric enzymes. J Med Chem 2012 ; 55 : 1287–1295. [CrossRef] [PubMed] [Google Scholar]
  24. Krimm I. INPHARMA-based identification of ligand binding site in fragment-based drug design Med Chem Commun 2012 ; 3 : 605–610. [Google Scholar]
  25. Aguirre C, ten Brinck T, Walker O, et al. Bcl-xL conformational change upon fragment-binding revealed by NMR. PLoS One 2013 ; 8 : e64400. [CrossRef] [PubMed] [Google Scholar]
  26. Mullard A. Protein-protein interaction inhibitors get into the groove. Nat Rev Drug Discov 2012 ; 11 : 173–175. [CrossRef] [PubMed] [Google Scholar]
  27. Morley AD, Pugliese A, Birchall K, et al. Fragment-based hit identification: thinking in 3D. Drug Discov Today 2013 ; 23 : 1221–1227. [CrossRef] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.